Press Releases
RSS feedGénéthon, the French AFM-Telethon laboratory, becomes the first not-for-profit to obtain authorization from ANSM to be a pharmaceutical manufacturer
Généthon, the AFM-Telethon laboratory, has received the authorization delivered by the National Agency for Drug Safety (ANSM) to become a pharmaceutical manufacturer. Its production center, Généthon BioProd, is now authorized to produce drugs for innovative treatments. This is a first for a laboratory created by an association of patients and financed thanks to the generosity … [Read more]
Myotubular Trust is supporting Généthon in developing gene therapy for Myotubular myopathy
The European charity Myotubular Trust announces its support to the development of a pre-clinical gene therapy trial for myotubular myopathy, a project co-ordinated by Dr. Anna Buj-Bello at Généthon (Evry, France). Read the press release
AFM-Téléthon and the National Seed Fund have joined forces
CDC Entreprises, a subsidiary of Caisse des Dépôts and a future bpifrance1 entity, has been mandated by the French government to manage the FNA as part of the Investing in the Future Programme (Programme d’Investissements d’Avenir). It is collaborating with AFM-Téléthon (French muscular dystrophy association organising French Téléthon), an association of patients and parents of patients, to help introduce … [Read more]
Chronic granulomatous disease : Genethon receives approval from the UK medicine regulatory agency to start a new clinical trial
On January 10th, the British Medicine and Healthcare Regulatory Agency (MHRA) approved Genethon’s Phase I / II gene therapy clinical trial application in X-linked chronic granulomatous disease (XCGD) to start at Great Ormond Street Hospital in London. Genethon is also seeking approval for this multicenter trial in Germany, Switzerland and France. In total the trial will include 20 patients … [Read more]
Rare diseases : 38 million Euro funding for research
European Union has announced 38 million Euro funding for research towards new treatments and for the development of a central global rare disease hub involving 70 institutions – including AFM-Telethon – that will allow scientists to share data from their genomics research projects. This will lead to faster diagnosis and better treatments and improve the … [Read more]
